Erectile Dysfunction Therapy: Recent Advances and Approaches
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Urology & Nephrology".
Deadline for manuscript submissions: 15 December 2026 | Viewed by 436
Editors
Interests: urology; urological surgery; andrology; laparoscopic surgery; robotic surgery
Interests: prostate cancer; prostate biopsies; bladder cancer; urogenital cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Erectile dysfunction (ED) affects millions worldwide and substantially reduces quality of life, intimate relationships, and psychological well‑being. Once attributed mainly to aging or psychogenic causes, ED is now understood as a multifactorial disorder with vascular, neurogenic, endocrine, iatrogenic and lifestyle-related contributors, requiring integrated diagnostic and therapeutic approaches. Advances across basic science, pharmacology, device engineering, and behavioral medicine have expanded therapeutic options, improved outcomes, and offered more personalized care pathways.
During the last decades, several advancements have been made in the therapeutic armamentarium of erectile dysfunction. Research into metabolic, hormonal, endothelial, and genetic biomarkers aims to stratify patients, predict treatment response, and tailor therapy regimens. Although phosphodiesterase type 5 inhibitors (PDE5is) comprise the initial option in these patients, novel drugs target alternate pathways or seek synergistic combinations to help PDE5i nonresponders. Regenerative medicine, including platelet‑rich plasma (PRP) injections and stem cell therapies, aims to restore vascular and neuronal function. Penile implants remain a durable solution for refractory ED, with improvements in mechanical reliability and cosmetic outcomes. Concerning less invasive neuromodulatory approaches, percutaneous nerve stimulation and wearable electrical stimulators are under investigation for neurogenic ED.
Therapies for erectile dysfunction are rapidly evolving. A combination of pharmacologic innovation, regenerative approaches, device refinement, psychosocial support, and digital health integration promises more effective, durable, and patient-centered treatment options.
We invite original research and comprehensive reviews that push the frontiers of erectile dysfunction research—especially work that integrates molecular and clinical biomarkers, novel pharmacologic targets and combination therapies, regenerative medicine, neuromodulation and device innovation, health-behavior interventions, and digital/precision-health approaches that improve access and outcomes. Submissions that elucidate mechanisms, validate predictive tools, report rigorously designed clinical trials, or present scalable implementation strategies are particularly welcome.
We encourage interdisciplinary contributions bridging urology, endocrinology, vascular biology, neuroscience, and behavioral medicine; our editorial process will prioritize methodological rigor, clinical relevance, and clear pathways to clinical impact to help your work reach clinicians, scientists, and policymakers shaping future standards of care.
Dr. Zisis Kratiras
Dr. Ilias Giannakodimos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- erectile dysfunction
- PDE5 inhibitors
- regenerative treatment
- neuromodulation
- penile implant
- pharmacology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
